Yesterday, medtech company Clincal Laserthermia Systems published its report for the second quarter of the year. The report highlighted, among other things, the company’s strengthened financial position and the three priority areas product offering, clinical evidence and the establishment of CLS & TRANBERG. CLS CEO Dan Mogren and VP Clinical Affairs Hoda Tawfik visited BioStock’s studio to tell us more in an interview in English.
See the interview with CLS’ CEO Dan Mogren and VP Clinical Affairs Hoda Tawfik below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.